Alto Neuroscience, Inc.

ANRO

$267M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaMOUNTAIN VIEW

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

8 upcoming, 0 past

Phase 2Next

ALTO-101 Phase 2 Results Expected

February 2026~ALTO-10182

Primary completion for ALTO-101 trial (NCT06502964) in Schizophrenia

Source

Phase 2

Placebo Phase 2 Results Expected

February 2026~ALTO-203 25 μg82

Primary completion for Placebo trial (NCT06502964) in Schizophrenia

Source

Phase 2

PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days Phase 2 Results Expected

February 2026~PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days60

Primary completion for PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days trial (NCT07326995) in Bronchial Asthma

Source

Phase 2

PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days Phase 2 Results Expected

March 2026~PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days30

Primary completion for PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days trial (NCT07324707) in Bronchial Asthma

Source

Phase 2

Placebo Phase 2 Results Expected

August 2026~ALTO-203 25 μg200

Primary completion for Placebo trial (NCT06656416) in Bipolar Disorder I or II With a Major Depressive Episode

Source

Phase 2

ALTO-100 Phase 2 Results Expected

August 2026~ALTO-100200

Primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Major Depressive Episode

Source

Phase 2

Placebo Phase 2 Results Expected

December 2026~ALTO-203 25 μg321

Primary completion for Placebo trial (NCT05922878) in Major Depressive Disorder

Source

Phase 2

ALTO-300 Phase 2 Results Expected

December 2026~ALTO-300321

Primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

ALTO-100

Phase 2

Bipolar Disorder I or II With a Major Depressive Episode

ALTO-300 oral (PO) tablet

Phase 2

Major Depressive Disorder

ALTO-100 PO tablet

Phase 2

Major Depressive Disorder

ALTO-300 PO Tablet

Phase 2

Major Depressive Disorder

ALTO-300

Phase 2

Major Depressive Disorder

ALTO-203 25 μg

Phase 2

Major Depressive Disorder

ALTO-101

Phase 2

Schizophrenia

PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days

Phase 2

Bronchial Asthma

PA1010

Phase 2

Chronic HBV Infection

PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days

Phase 2

Bronchial Asthma

PA9159 nasal spray solution, 10 μg once daily for 14 days

Phase 2

Allergic Rhinitis

Drug Name	Phase	Indication	Designations
ALTO-100	Phase 2	Bipolar Disorder I or II With a Major Depressive Episode	-
ALTO-300 oral (PO) tablet	Phase 2	Major Depressive Disorder	-
ALTO-100 PO tablet	Phase 2	Major Depressive Disorder	-
ALTO-300 PO Tablet	Phase 2	Major Depressive Disorder	-
ALTO-300	Phase 2	Major Depressive Disorder	-
ALTO-203 25 μg	Phase 2	Major Depressive Disorder	-
ALTO-101	Phase 2	Schizophrenia	-
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days	Phase 2	Bronchial Asthma	-
PA1010	Phase 2	Chronic HBV Infection	-
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days	Phase 2	Bronchial Asthma	-
PA9159 nasal spray solution, 10 μg once daily for 14 days	Phase 2	Allergic Rhinitis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ANRO News